Anti-TF Antibody-Drug Conjugate Dosing Regimen for Solid Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for solid cancers expressing tissue factor (TF) lack effective dosing regimens that balance efficacy and safety, particularly due to TF's ubiquitous expression in healthy tissues and rapid internalization, leading to potential increased side effects with frequent dosing.
Innovation Solution
A new dosing regimen for anti-TF antibody-drug conjugates involving administration once a week for three consecutive weeks followed by a one-week rest period, with doses between 0.8 mg/kg and 2.4 mg/kg, to enhance therapeutic efficacy while maintaining tolerability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If frequent dosing is used to enhance therapeutic efficacy, then treatment effectiveness is improved, but side effects increase due to TF's ubiquitous expression in healthy tissues
Solution Approach 1:
The patent implements a periodic dosing regimen consisting of three consecutive weekly doses followed by a one-week rest period, creating a four-week treatment cycle. This periodic action allows the drug to accumulate sufficient therapeutic effect during the three-dose phase while the rest period enables recovery and reduction of toxic effects from ubiquitous tissue expression, thereby resolving the contradiction between efficacy and side effects
2Reliability
If higher doses are administered to overcome rapid internalization of TF, then therapeutic effect is enhanced, but safety and tolerability deteriorate
Solution Approach 1:
The patent optimizes the dosage parameter to a specific range of 0.8-2.4 mg/kg administered weekly, rather than using higher single doses. This parameter change, combined with the periodic dosing schedule, maintains sufficient drug levels to overcome TF's rapid internalization while keeping the total weekly exposure within safe tolerability limits, thus resolving the contradiction between therapeutic effect and safety
3Duration of action of moving object
If continuous dosing is used to maintain drug levels, then treatment effectiveness is improved, but accumulation of toxic effects occurs
Solution Approach 1:
The patent introduces a one-week rest period after three consecutive weekly doses, creating an on-off dosing pattern. During the three-dose phase, the drug maintains therapeutic effect; during the rest week, the drug is withheld to allow clearance and reduction of accumulated toxic effects. This periodic interruption prevents continuous toxic accumulation while maintaining overall treatment effectiveness
Data Source
AI summary
Anti-TF antibody drug conjugate and pharmaceutical compositions comprising the antibody drug-conjugate for use in the treatment of a solid cancer comprising administering to a subject a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an anti-TF antibody drug conjugate once a week for three consecutive weeks followed by a one week resting period without any administration of anti-TF ADC so that each cycle time is 28 days including the resting period.